Business
NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
RA'ANANA, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company") today announced that it has received a $580,000 commercial purchase order from NYU Langone Hospital in New York City (“NYU Langone”) for the Company’s FDA-cleared ART100 extracorporeal blood circulation systems. The order was placed through Inspira’s U.S. distributor following the successful completion of a multi-patient clinical evaluation at the hospital, a
About this update from Qtrex Quantum Ltd.
[{"type":"image","alt":"Inspira Technologies","displaySize":"","headline":null,"caption":"Inspira Technologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zHjuu3EuFqEJ1Sil3g6__w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zHjuu3EuFqEJ1Sil3g6__w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71}},"lazy":false},{"type":"text","content":"RA'ANANA, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company") today announced that it has received a $580,000 commercial purchase order from NYU Langone Hospital in New York City (“NYU Langone”) for the Company’s FDA-cleared ART100 extracorporeal blood circulation systems. The order was placed through Inspira’s U.S. distributor following the successful completion of a multi-patient clinical evaluation at the hospital, and the systems are scheduled for immediate fulfillment. This commercial milestone is in parallel with the Company’s previously disclosed active strategic process involving the ART100 platform and broader medical assets.","length":743,"tagName":"p"},{"type":"text","content":"The purchase order follows the successful completion of an extensive hospital-based clinical evaluation, during which ART100 systems were deployed in the treatment of more than 30 patients across a broad range of cardiopulmonary and surgical cases. The evaluation provided NYU Langone with direct operational experience integrating the ART100 platform into the hospital workflows and led directly to the hospital’s decision to transition from clinical assessment to commercial procurement.","length":489,"tagName":"p"},{"type":"text","content":"“NYU Langone’s transition from hospital-based evaluation to commercial purchase reflects the operational value of the ART100 platform in real hospital use,” said Mike Hershkovitz, VP of Global Sales at Inspira Technologies. “This order provides an important hospital reference as we conti...